Nonalcoholic steatohepatitis (NASH) is a kind of nonalcoholic fatty liver disease (NAFLD) in which fat accumulates abnormally in the liver. This may induce inflammation and liver cell damage, resulting in liver fibrosis or scarring, which can proceed to cirrhosis or liver cancer. NASH is a chronic, silent illness with little or no symptoms that frequently go unnoticed and undiagnosed. Diabetes, obesity, insulin resistance, high cholesterol levels, and metabolic syndrome are all risk factors for NASH.
A Comprehensive Market Analysis
DataM Intelligence’s report on the non-alcoholic steatohepatitis treatment market provides valuable insights into the latest trends and developments in the industry. It offers a comprehensive overview of the market’s competitive landscape, key players, and market dynamics, allowing you to make informed decisions.
Furthermore, the report offers precise forecasts for the market’s development over the forecast period, highlighting the key trends, growth opportunities, and market potential. This helps readers to gain a clear understanding of the market’s landscape and develop more effective strategies.
Market Drivers
Rise in NASH-affected population to propel market growth
The increase in the global NASH-affected population is likely to drive the development of the global non-alcoholic steatohepatitis (NASH) treatments and diagnostics market throughout the forecast period.
According to the Global Liver Institute (or International NASH Day), around 25-30% of individuals globally have NAFLD, and approximately 2-6% have NASH, with the incidence of NASH potentially increasing by more than 50% by 2030. This is likely to raise demand for safe and effective NASH therapies and diagnostics, propelling the NASH therapeutics and diagnostics market forward.
Market Opportunities
The rising need for safe and effective NASH therapies and diagnostics will provide considerable growth potential for participants in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market.
Emerging Market Trend
With the rising frequency of NASH, the need for innovative therapies and diagnostics is also rising rapidly. When a microscopic examination of the tissue reveals inflammation and damage to the liver cells as well as fat, NASH is identified. Market participants are concentrating on creating innovative diagnostic tests that may directly target developed markets and benefit both patients and the enterprise. This trend is projected to continue during the forecast period, propelling the NASH therapies and diagnostics market forward.
Market Key Players
The global market players operating in the non-alcoholic steatohepatitis treatment market are
- Allergan plc.
- Pfizer Inc
- Gilead Sciences, Inc.
- Novartis AG
- Intercepts Pharmaceuticals
The major players are adopting several growth strategies such as platform launches, acquisitions, licensing, mergers and collaborations, which are contributing to the growth of the non-alcoholic steatohepatitis treatment market globally.
For businesses, investors, and decision-makers in the non-alcoholic steatohepatitis treatment market, conducting a thorough market analysis is crucial in staying ahead of the competition. By examining market drivers, challenges, and opportunities, recent developments stakeholders can comprehensively understand the current market landscape and future projections.
To Know More Download Sample
